Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity

Background:Current biomarkers in ulcerative colitis (UC) are limited by their performance, cost, and limited availability in daily practice. This study examined alterations in the leukocyte profiles as biomarkers of UC activity, including the effects of age, gender, and medications. Methods:Case–control study that included 110 UC subjects, 75 subjects with Clostridium difficile infection, and 75 non-inflammatory bowel disease (IBD) subjects, randomly selected from a single-institution IBD database. Mean values of neutrophils (N), lymphocytes (L), monocytes (M) and their ratios were compared between groups. Receiver operator curve analyses assessed the performance of each biomarker in discriminating disease states. Subgroup analyses examined leukocytes profiles with endoscopic activity. Results:Elevated monocyte counts and decreased L/M values significantly differed between subjects with active UC and UC in remission and performed better than the other leukocyte profiles. A monocyte count of 483 and L/M ratio of 3.1 were 60% sensitive and had a specificity of 61% and 53%, respectively for active UC. Monocyte count >860 and L/M value <1.6 had a 75% positive predictive value for UC activity. Those markers also correlated with endoscopically active disease. L/M and N/L values performed best at differentiating active UC from non-IBD controls, whereas N/L and N values performed best at differentiating from C. difficile controls. Conclusions:Monocytosis and a low L/M ratio might be effective, readily available, and low-cost biomarkers to identify disease activity in UC patients. N/L values were more effective in distinguishing active UC patients from patients without IBD and those with C. difficile infection.

[1]  B. Abraham,et al.  Fecal calprotectin: controlling the cost of care. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Kori L Wallace,et al.  Immunopathology of inflammatory bowel disease. , 2014, World journal of gastroenterology.

[3]  J. Fletcher,et al.  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.

[4]  A. Schoepfer,et al.  Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.

[5]  G. Zararsiz,et al.  Neutrophil–Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis , 2013, Journal of clinical laboratory analysis.

[6]  T. Kim,et al.  Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis , 2013, Digestive Diseases and Sciences.

[7]  B. Shirts,et al.  The Entire Predictive Value of the Prometheus IBD sgi Diagnostic Product May be Due to the Three Least Expensive and Most Available Components , 2012, The American Journal of Gastroenterology.

[8]  Y. Beyazit,et al.  Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. , 2012, Clinics and research in hepatology and gastroenterology.

[9]  M. Ciorba,et al.  Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.

[10]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[11]  T. Macdonald,et al.  Regulation of homeostasis and inflammation in the intestine. , 2011, Gastroenterology.

[12]  J. Lewis The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.

[13]  J. Gisbert,et al.  Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. , 2009, Inflammatory bowel diseases.

[14]  M. Silverberg,et al.  A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  L. Cleland,et al.  Treatment‐induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis , 2009, Internal medicine journal.

[16]  B. Zhong,et al.  Significance of white blood cell count and its subtypes in patients with acute coronary syndrome , 2009, European journal of clinical investigation.

[17]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[18]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[19]  K. Faber,et al.  Monocytes and their pathophysiological role in Crohn’s disease , 2008, Cellular and Molecular Life Sciences.

[20]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[21]  A. Zinsmeister,et al.  Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[22]  Y. Saeki,et al.  Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy , 1999, Journal of Clinical Immunology.

[23]  C. Seal,et al.  The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis , 2001, American Journal of Gastroenterology.

[24]  S. Targan,et al.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[25]  Y. Saeki,et al.  Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. , 1999, Journal of clinical immunology.

[26]  E. Irvine,et al.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.

[27]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[28]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[29]  D. Jewell,et al.  Monocytes in inflammatory bowel disease: absolute monocyte counts. , 1980, Journal of clinical pathology.

[30]  C. Charland,et al.  The subpopulations of circulating white blood cells in inflammatory bowel disease. , 1976, Gastroenterology.